

IN SILICO DESIGN, ANTIBACTERIAL AND ANTIFUNGAL EVALUATION OF TRITERPENOID GLYCOSIDE SAPOLIDE FROM *SAPONARIA OFFICINALIS* L.Ashurova L¹., Sasmakov S¹., Ramazonov N¹., Aliyeva Sh²., Garaev E. ²**Abstract**

The aqueous and chloroform fractions of the methanolic extract obtained from the aerial parts of *Saponaria officinalis* L. were evaluated for their antibacterial and antifungal activities. The aqueous fraction exhibited the highest antibacterial activity, with inhibition zones measuring 12 mm against *Bacillus subtilis*, 13 mm against *Staphylococcus aureus*, 18 mm against *Escherichia coli*, and 14 mm against *Pseudomonas aeruginosa*. In silico PASS predictions indicated that sapolide, a major constituent, possesses high probabilities of biological activity, including 92.4% for general antineoplastic effects, 88.7% for pro-apoptotic activity, and 85.4% for antineoplastic activity against lung cancer. Pharmacokinetic analysis revealed that sapolide complies with Lipinski's "rule of five," shows good oral bioavailability, and meets the criteria for drug-likeness. Molecular docking analysis revealed that sapolide binds to Aurora B kinase with binding energies ranging from -10.7 to -7.4 kcal/mol, and to the Pregnane X Receptor with energies from -8.8 to -7.5 kcal/mol. These interactions suggest stable and specific binding, with the sapolide-Aurora B kinase complex, in particular, supporting its potential as a novel inhibitor of this enzyme with antitumor activity. In summary, these findings highlight sapolide as a promising bioactive natural compound with both antimicrobial effects and significant therapeutic potential in oncology.

Keywords: *Saponaria officinalis* L., sapolide, *in silico*, molecular docking

INTRODUCTION

The genus *Saponaria* (Caryophyllaceae) comprises about 40 species distributed across the temperate regions of Eurasia, with a center of diversity in the Mediterranean area [1]. Six species are endemic to the territory of Uzbekistan. Among them, *Saponaria officinalis* L. is particularly notable for its exceptionally high saponin content, which constitutes 20–35% of the root dry mass. Phytochemical investigations of its roots have led to the isolation of various

metabolites, including carbohydrates and triterpenoid glycosides such as saponazides [2] and saponariosides A–M [3–5] together with four aglycones: hederagenin, hydroxyhederagenin, gypsogenin, and quillaic acid [6]. In addition, the leaves of *S. officinalis* contain alkaloids, ascorbic acid, and flavonoids such as vitexin, saponarin, and saponaretin [7,8]. In traditional medicine, decoctions and infusions prepared from the roots and leaves of *S. officinalis* have long been employed for the treatment of



© ATUJ and The Author(s) 2026. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

respiratory diseases, gastrointestinal disorders, rheumatism, polyarthritis, psoriasis, lichen planus, eczema, and prostate adenoma [9,10]. Recent phytochemical studies of the aerial parts of *S. officinalis* growing in Uzbekistan resulted in the isolation of a new natural saponin, sapolide [11]. This compound had previously only been obtained synthetically through acid hydrolysis of albigenic acid [12]. In modern pharmaceutical research, computer-aided drug design (CADD) has become an essential tool for the discovery of new therapeutic agents with improved efficacy and safety profiles [14]. Among the most widely applied strategies are structure-based drug design (SBDD) and ligand-based drug design (LBDD), which allow the evaluation of biological activity, toxicity, physicochemical parameters, and pharmacokinetic properties of candidate molecules [15].

The present study we evaluate the antibacterial and antifungal activities of extracts and fractions from *S. officinalis* and perform an *in silico* investigation of sapolide, focusing on its predicted biological activity, safety, solubility, bioavailability, pharmacokinetics, and drug-likeness.

Yazışma üçün əlaqə:

Ashurova L¹., Sasmakov S¹., Ramazonov N¹., Aliyeva Sh²., Garaev E. ²

1 S.Yu. Yunusov Institute of the Chemistry of Plant Substances
AS RUz, Tashkent, Uzbekistan,

¹E-mail: ashurova_lola1985@mail.ru

2 Азербайджанский Медицинский Университет, Баку,
Азербайджан

² E-mail: eldargar@mail.ru

MATERIALS AND METHODS

Plant material. The aerial parts of *Saponaria officinalis* were used in this study. The plant material was collected in July 2020 during the full flowering stage in the Yunusabad district of Tashkent, Uzbekistan. The samples were air-dried, packed in paper bags, and stored in a cool, dark place until further use.

Extraction and isolation. The powdered air-dried aerial parts of the plant (1 kg) were extracted five times with methanol at room temperature. After vacuum evaporation, a crude extract (445 g) was obtained, which was suspended in water (5 L) and successively fractionated with chloroform, ethyl acetate, and *n*-butanol.

The *n*-butanol extract (120 g) was chromatographed on a silica gel column (0.03–0.200 mm) using a gradient solvent system of CHCl₃–CH₃OH (1:0 → 0:1), yielding four fractions (A–D). Fraction 1 (56 g) was rechromatographed on silica gel (0.040–0.063 mm) with a gradient system of CHCl₃–CH₃OH (50:1 → 0:1), resulting in ten subfractions (A1.1–A1.10). Subfraction A1.1–5–6 (48 mg) was further purified by preparative TLC (CHCl₃–CH₃OH, 40:1), affording pure sapolide (20 mg). The yield was 0.002% relative to the air-dried plant material.

Determination of antimicrobial activity.

The fractions of the methanolic extract of *Saponaria officinalis* were evaluated for antibacterial and antifungal activities using a modified agar diffusion method [13].

***In silico* analysis of sapolide.** The biological activity of sapolide was evaluated using the PASS Online, SwissADME, and SwissTarget programs.

PASS Online (<https://www.way2drug.com>) was used to predict the biological activity of sapolide based on structure–activity relationship analysis [16].

SwissADME (SIB, www.expasy.org/resources/swissadme)

was used to evaluate the physicochemical properties, solubility, bioavailability, and pharmacokinetic parameters.

SwissTarget (SIB, www.expasy.org/resources/swisstargetprediction) was used to predict potential protein targets.

Molecular docking was performed using AutoDock Vina 4.3, which was downloaded from the official website (www.scripps.edu). The AutoDock tools were used to generate the PDBQT file. All docking calculations were carried out with

the AutoDock Vina 4.3 software package in combination with auxiliary tools AutoDock Tools and PyMOL.

The crystalline structures of macromolecules were obtained from the **RCSB Protein Data Bank** (www.rcsb.org/pdb/). All calculations were performed in AutoDock Vina 4.3 using AutoDock Tools and PyMOL.

RESULTS AND DISCUSSION

Determination of antimicrobial and antifungal activity. The results of the antimicrobial activity of *Saponaria officinalis* extracts are presented in Table 1.

Table 1. Antimicrobial and antifungal activity of the fractions of the methanolic extract of *Saponaria officinalis*

Samples	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>C. albicans</i>
<i>S. officinalis</i> (aqueous fraction)	12.04±0.10	13.08±0.12	18.08±0.12	14.12±0.13	NA
<i>S. officinalis</i> (chloroform fraction)	7.04±0.10	6.08±0.12	6.08±0.12	7.12±0.13	NA
Ampicillin (10 µg/disc)	28.04±0.10	27.08±0.12	NT	NT	NT
Ceftriaxone (30 µg/disc)	NT	NT	26.08±0.12	28.12±0.13	NT
Fluconazole (25 µg/disc)	NT	NT	NT	NT	30.04±0.10


*NA – not active; NT – not tested

The results (Table 1) showed that the tested extracts inhibited the growth of both Gram-positive and Gram-negative bacterial test strains. The aqueous fraction exhibited the highest antibacterial activity, with inhibition zones measuring 12 mm for *Bacillus subtilis*, 13 mm for *Staphylococcus aureus*, 18 mm for

Escherichia coli, and 14 mm for *Pseudomonas aeruginosa*.

In silico study of sapolide. The *in silico* predictions of the biological activity of sapolide were obtained using the *PASS Online* program by inputting the chemical structure of the compound. The results were considered within

Table 2. Predicted biological activity of the compound sapolide — Pa (0.001–100)

Pa	Pi	Biological activity	Chemical formula of sapolide
0,924	0,005	Antineoplastic	
0,887	0,005	Apoptosis agonist	
0,854	0,004	Antineoplastic (lung cancer)	
0,854	0,004	Caspase 3 stimulant	
0,841	0,002	Transcription factor NF kappa B stimulant	
0,841	0,002	Transcription factor stimulant	
0,827	0,003	Chemopreventive	
0,803	0,003	Nitric oxide antagonist	
0,797	0,002	Caspase 8 stimulant	
0,753	0,005	Phosphatase inhibitor	
0,651	0,009	Hepatoprotectant	

According to the predictions of the PASS Online service (Table 1), the compound sapolide demonstrated the highest probabilities of activity: 0.924 (92.4%) for antineoplastic activity, 0.887 (88.7%) for apoptosis agonist properties, and 0.854

(85.4%) for antineoplastic (lung cancer) activity.

The prediction of physicochemical properties, pharmacokinetic parameters, and drug-likeness indicators of sapolide was carried out using the SwissADME program (Table3).

Table 3. Predicted parameters (physicochemical properties, solubility, pharmacokinetic characteristics, and drug-likeness) of sapolide according to the SwissADME program

Physicochemical Properties		Water Solubility	
Name		Log S (ESOL)	-6.33
Formula	C ₃₀ H ₄₆ O ₅	Solubility	2.27e-04 mg/ml ; 4.66e-07 mol/l
Molecular weight	486.68 g/mol	Class	Poorly soluble
Num. heavy atoms	35	Log S (Ali)	-7.14
Num. arom. heavy atoms	0	Solubility	3.50e-05 mg/ml ; 7.19e-08 mol/l
Fraction Csp3	0.93	Class	Poorly soluble
Num. rotatable bonds	1	Log S (SILICOS-IT)	-5.61
Num. H-bond acceptors	5	Solubility	1.19e-03 mg/ml ; 2.45e-06 mol/l
Num. H-bond donors	2	Class	Moderately soluble
Molar Refractivity	135.93	Pharmacokinetics	
TPSA	83.83 Å ²	GI absorption	High
Lipophilicity		BBB permeant	No
Log Po/w (iLOGP)	3.28	P-gp substrate	Yes

Log Po/w (XLOGP3)	5.62	CYP1A2 inhibitor	No
Log Po/w (WLOGP)	5.06	CYP2C19 inhibitor	No
Log Po/w (MLOGP)	4.14	CYP2C9 inhibitor	No
Log Po/w (SILICOS-IT)	5.13	CYP2D6 inhibitor	No
Consensus Log Po/w	4.65	CYP3A4 inhibitor	No
Druglikeness		Log Kp (skin permeation)	-5.28 cm/s
Lipinski	Yes; 0 violation		
Ghose	No; 3 violations: MW>480, MR>130, #atoms>70		
Veber	Yes		
Egan	Yes		
Muegge	No; 1 violation: XLOGP3>5		
Bioavailability Score	0.55		

Based on the results obtained using the SwissADME program (Table 2), it can be predicted that sapolide meets the pharmacokinetic criteria (absorption, distribution, metabolism, and excretion) as well as the physicochemical requirements (no more than five hydrogen bond donors, ten hydrogen bond acceptors, and a molecular weight not exceeding 500 Da, among others) defined by Lipinski's "Rule of Five." The compound demonstrates

good bioavailability and satisfies the criteria for drug-likeness. The SwissTarget program compares the chemical structure of the studied compound with a database of known molecules and predicts similar interactions based on this comparison. Using the SwissTarget program, various macromolecules that may serve as potential biological targets for sapolide were predicted (Figure 1).




Figure 1. Biological targets of sapolide (%)

As shown in Figure 1, the results obtained from the SwissTarget program predict that sapolide interacts with macromolecules in the following order: oxidoreductases

(6.7%), kinases (13.3%), phosphatases (33.3%), and so on.

Molecular docking. Using AutoDock Vina 4.3, molecular docking was performed to predict the binding mode and affinity of the sapolide ligand to the biological targets—macromolecules identified with the SwissTarget program. AutoDock Vina 4.3

predicts the optimal spatial orientation of the ligand and calculates the interaction energy between the ligand and the macromolecule.

Aurora B Kinase (PDB code: 4AF3)




Figure 2. Molecular docking representation of sapolide with Aurora B kinase (2D – left, 3D – right)

Table 4. Binding affinity of sapolide to the macromolecule Aurora B kinase

Mode	Affinity (kcal/mol)	RMSD i.b.	RMSD u.b.
1	-10.7	0.000	0.000
2	-8.7	15.386	18.509
3	-8.4	29.458	32.767
4	-8.4	29.482	32.357
5	-8.4	2.177	4.492
6	-8.1	29.956	33.367
7	-7.7	22.817	25.306
8	-7.5	30.390	33.425
9	-7.4	29.762	32.440

As shown in Figure 2, two oxygen-containing fragments at positions 16 and 28 are involved in interactions with TYR A:141 (interaction between the carbonyl

group of sapolide and the hydroxyl group of tyrosine) and with GLN D:858 (interaction between the hydroxyl group of sapolide and the glutamine residue of the

protein). The blue areas indicate potential regions of electron density, representing electrostatic interactions that correspond to hydrogen bonds. Green dashed lines depict hydrogen bonds between the sapolide ligand and the amino acid residues of Aurora B kinase. The residues shown in green circles are amino acids located approximately 4–5 Å from the ligand, indicating possible hydrophobic, π - π , van der Waals, and other interactions. Molecular docking determines the binding affinity and potential biological activity of a low-molecular-weight compound. In docking analysis, it is generally accepted that a ligand with a lower (more negative) binding energy to a macromolecule indicates stronger potential binding [17]. The active binding sites of the Aurora B kinase protein are as follows:

- Hydrophobic: LEU D:865, PRO D:862, ILE D:855, PHE A:101, PRO A:336/337/158, TYR A:156

Pregnane X receptor (PDB code : 8SVN)





Figure 3. Molecular docking representation of sapolide with the Pregnane X receptor (2D – left, 3D – right)

- Polar/charged: HIS A:133/134, ARG A:139, LYS A:215, GLU A:155, SER A:338

1. Hydrogen bonds (green dashed lines): Classical hydrogen bonds are formed between the ligand molecule and the following amino acid residues of the protein: GLN (D:858), TYR (A:141).
2. Van der Waals interactions (light green lines): The ligand molecule establishes weak Van der Waals interactions with multiple amino acid residues of Aurora B kinase. These interactions are observed with the following amino acids: ILE (D:855), TYR (D:859), PHE (A:101), GLU (A:155), TYR (A:156), PRO (A:158), LEU (A:210), GLY (A:209), LYS (A:215), PRO (A:135, A:336, A:337, D:862, D:863), LEU (D:865), HIS (A:133, A:134), SER (A:338). These weak hydrophobic interactions contribute to the proper positioning of the ligand within the active site and enhance the overall stability of the binding.

Table 5. Binding affinity of sapolide to the macromolecule Pregnane X receptor

Mode	Affinity (kcal/mol)	RMSD l.b.	RMSD u.b.
1	-8.8	0.000	0.000
2	-8.0	11.106	14.503
3	-7.9	22.024	24.219
4	-7.9	2.017	3.371
5	-7.9	21.421	24.724
6	-7.9	27.905	31.026
7	-7.8	22.384	25.223
8	-7.6	21.007	25.321
9	-7.5	2.110	8.677

1. From Figure 3, the following types of interactions can be identified:

2. Hydrogen bonds (green dashed lines): Classical hydrogen bonds are formed between the hydrophilic groups of the ligand and the residues ARG (A:173), LYS (A:170), and HIS (A:168) of the PXR protein. These bonds enhance the binding selectivity and stability of the complex, stabilizing the ligand within the active site of the macromolecule.

3. π -Alkyl interactions (purple dashed lines):

π -Alkyl interactions occur between the aromatic rings of the ligand and the residues LYS (A:252) and TYR (A:249) of the protein. The interaction of aromatic residues with the saturated regions of the ligand further enhances the stability of the complex.

4. C–H or Van der Waals interactions (light green lines):

The ligand molecule forms weak Van der Waals interactions with several amino acid residues of the Pregnane X Receptor

(PXR, PDB: 8SVN). These interactions are observed with the residues ASN (A:171), PHE (A:169), PHE (A:172), THR (A:248), THR (A:422), and PRO (A:423). These weak interactions contribute to the proper positioning of the ligand within the active site and help maintain its stability.

A carbon–hydrogen bond is observed between the ligand and the residue ASP (A:245). This weak interaction further stabilizes the position of the ligand.

CONCLUSION

The aqueous and chloroform fractions of the methanolic extract of the aerial parts of *Saponaria officinalis* L. exhibited antimicrobial activity, with the aqueous fraction showing the strongest inhibition against both Gram-positive and Gram-negative bacterial strains. This effect is most likely associated with the high content of saponins. The triterpenoid glycoside sapolide, isolated from this plant, demonstrated promising pharmacological potential in silico. PASS predictions indicated high probabilities for antineoplastic activity, apoptosis agonist

properties, and activity against lung cancer. Pharmacokinetic and physicochemical analyses confirmed its compliance with Lipinski's "Rule of Five," good oral bioavailability, and overall drug-likeness. Molecular docking revealed strong and stable binding of sapolide to Aurora B kinase and the Pregnane X receptor, with binding energies in the range of -10.7 to -7.4 kcal/mol and -8.8 to -7.5 kcal/mol, respectively. These interactions suggest that sapolide may serve as a promising ligand and potential inhibitor of Aurora B kinase, supporting its further development as a candidate for antitumor therapy.

Overall, these findings highlight sapolide as a bioactive natural compound with dual antimicrobial and anticancer potential, warranting further in vitro and in vivo investigations.

REFERENCES

1. Dashti, A., (2018). Role of seed micro-morphology in the taxonomy of *Saponaria* (Caryophyllaceae). *Iranian Journal of Botany*, 24(2), 130–137. [10.22092/ijb.2018.123401.1213](https://doi.org/10.22092/ijb.2018.123401.1213).
2. Satish, Ch., Dharmendra, S Rawat., Arun, Bhatt., Phytochemistry and pharmacological activities of *Saponaria officinalis* L.: A review. (2021). *Notulae Scientia Biologicae* 13(1), 10809. <https://doi.org/10.15835/nsb13110809>.
3. Koike, K., Jia, Z., & Nikaido, T. (1999). New triterpenoid saponins and sapogenins from *Saponaria officinalis*. *Journal of Natural Products*, 62(12), 1655–1659. <https://doi.org/10.1021/np990311r>.
4. Jia, Z., Koike, K., & Nikaido, T. (1998). Major triterpenoid saponins from *Saponaria officinalis*. *Journal of Natural Products*, 61(11), 1368–1373. <https://doi.org/10.1021/np980167u>.
5. Jia, Z., Koike, K., & Nikaido, T. (1999). Saponarioside C, the first α -D-galactose containing triterpenoid saponin, and five related compounds from *Saponaria officinalis*. *Journal of Natural Products*, 62(4), 449–453. <https://doi.org/10.1021/np980434w>.
6. Smulek, W., Zdarta, A., Pacholak, A., Zgoła-Grzeškowiak, A., Marczak, Ł., Jarzębski, M., & Kaczorek, E. (2017). *Saponaria officinalis* L. extract: Surface active properties and impact on environmental bacterial strains. *Colloids and Surfaces B: Biointerfaces*, 150, 209–215. <https://doi.org/10.1016/j.colsurfb.2016.11.035>.
7. Endonova, G. B., Antsupova, T. P., & Zhamsaranova, S. D. (2015). Study of Flavonoid and Antioxidant Activity of *Saponaria officinalis*. *Biosciences Biotechnology Research Asia*. 12(3), 2017–2021. <http://dx.doi.org/10.13005/bbra/1869>.
8. Lu, Y., Van, D., Deibert, L., Bishop, G., Balsevich, J. (2015). Antiproliferative quillaic acid and gypsogenin saponins from *Saponaria officinalis* L. roots. *Phytochemistry* 113, 108–120. <https://doi.org/10.1016/j.phytochem.2014.11.021>
9. Charalambous, D., Christoforou, M., Christou, K., Christou, M., Ververis, A., Andreou, M., & Pantelidou, M. (2024). Saponin and phenolic composition and assessment of biological activities of *Saponaria officinalis* L. root extracts. *Plants*, 13(14). <https://www.mdpi.com/2223-7747/13/14/1982>.
10. Ashurova, L. N., Bobakulov, Kh. M., Ramazonov, N. Sh., Sasmakov, S. A., Ashirov, O. N., Azimova, Sh. S., &

Abdullaev, N. D. (2021). Essential oil from the aerial part of *Saponaria griffithiana* and *Saponaria officinalis*. *Chemistry of Natural Compounds*, 57(5), 970–972. <https://doi.org/10.1007/s10600-021-03527-3>.

11. Kubota, T., Kitatani, H., & Hinoh, H. (1969). Isomerisation of quillaic acid and echinocystic acid with hydrochloric acid. *Tetrahedron Letters*, 10, 771–774. [https://doi.org/10.1016/S0040-4039\(01\)87805-9](https://doi.org/10.1016/S0040-4039(01)87805-9).

12. Wayne, P. A. (2009). *Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement (CLSI document M100-S19)*. Clinical and Laboratory Standards Institute, Wayne, PA, USA.

13. Vasiliev, P. M., Golubeva, A. V., Koroleva, A. R., Perfiliev, M. A., &

Kochetkov, A. N. (2023). *Title of the article. Safety and Risk of Pharmacotherapy*, 11(4), 390–408. <https://doi.org/10.30895/2312-7821-2023-11-4-390-408>.

14. Garaev, E. A., Huseynguliyeva, K. F. (2021). *Modern approaches to assessing the toxicity of xenobiotics*. *Azerbaijan Medical Journal*, 2, 95–100.

16. D.A. Filimonov, A.A. Lagunin, T.A. Gloriozova, A.V. Rudik, D.S. Druzhilovsky, P.V. Pogodin, V.V. Poroykov, *Chemistry of Heterocyclic Compounds*, 3, 483–499 (2014).

17. K.V. Goldaeva, *Journal of Bioinformatics and Genomics*, 4(26) (2024).

<https://doi.org/10.60797/jbg.2024.26.6>

ИССЛЕДОВАНИЕ АНТИБАКТЕРИАЛЬНОЙ И ПРОТИВОГРИБКОВОЙ АКТИВНОСТИ ФРАКЦИИ *SAPONARIA OFFICINALIS* L. И IN SILICO АНАЛИЗ ТРИТЕРПЕНОВОГО ГЛИКОЗИДА САПОЛИДА

Ашурова Л.¹, Сасмаков С.¹, Рамазонов Н.¹, Алиева Ш.², Гараев Э.²

¹Институт химии растительных веществ имени академика С.Ю.Юнусова АН РУз, Ташкент, Узбекистан

¹E-mail: ashurova_lola1985@mail.ru

²Азербайджанский Медицинский Университет, Баку, Азербайджан

E-mail: eldargar@mail.ru

Резюме

Исследованы водные и хлороформные фракции метанольного экстракта надземной части *Saponaria officinalis* L. на антибактериальную и противогрибковую активность. Наибольшая антибактериальная активность отмечена у водной фракции: зона ингибирования составила 12 мм для *Bacillus subtilis*, 13 мм для *Staphylococcus aureus*, 18 мм для *Escherichia coli* и 14 мм для *Pseudomonas aeruginosa*.

Согласно прогнозам *in silico*, саполид демонстрирует высокую биологическую активность: 92,4% — антинеопластическая активность, 88,7% — агонистические свойства в отношении апоптоза, 85,4% — антинеопластическая активность при раке лёгких. Фармакокинетический анализ показывает, что саполид соответствует «правилу пяти» Липинского, обладает хорошей биодоступностью и удовлетворяет критериям лекарственной схожести.

Молекулярный докинг показал, что саполид связывается с Aurora B Kinase с энергией от $-10,7$ до $-7,4$ ккал/моль, а с Pregnane X Receptor — от $-8,8$ до $-7,5$ ккал/моль. Это указывает на то, что саполид может быть потенциальным субстратом для этих мишеней. Комплекс саполида с Aurora B Kinase вероятно стабилен и биологически активен. Полученные результаты подтверждают специфичное и прочное связывание саполида с Aurora B Kinase, что делает его перспективным соединением для разработки новых ингибиторов данного фермента с противоопухолевой активностью. Аналогично, комплекс с Pregnane X Receptor указывает на потенциальную биологическую активность саполида как лиганда для этой макромолекулы.

Ключевые слова: *Saponaria officinalis* L., саполид, *in silico*, молекулярный докинг

SAPONARIA OFFICINALIS L. FRAKSIYALARININ ANTIBAKTERIAL VƏ ANTIFUNGAL AKTIVLIYININ TƏDQIQI VƏ TRITERPEN QLIKOZIDI SAPOLIDIN IN SILICO ANALIZI

Aşurova L.¹, Sasmakov S.¹, Ramazonov N.¹, Əliyeva Ş.², Qarayev E.²

1. Özbəkistan EA-nın akademik S.Yu. Yunusov adına Bitki Maddələri Kimyası İnstitutu, Daşkənd şəh., Özbəkistan

E-mail: ashurova_lola1985@mail.ru

2. Azərbaycan Tibb Universiteti, Bakı, Azərbaycan

E-mail: eldargar@mail.ru

Xülasə

Saponaria officinalis L. bitkisinin yerüstü hissəsinin metanol ekstraktının sulu və xloroform fraksiyalarının antibakterial və antifungal aktivliyi tədqiq edilmişdir. Ən yüksək antibakterial aktivlik sulu fraksiyada müşahidə olunmuşdur: inhibisiya zonası *Bacillus subtilis* üçün 12 mm, *Staphylococcus aureus* üçün 13 mm, *Escherichia coli* üçün 18 mm və *Pseudomonas aeruginosa* üçün 14 mm təşkil etmişdir. *In silico* proqnozlara əsasən, sapolid yüksək bioloji aktivlik nümayiş etdirir: 92,4% — antineoplastik aktivlik, 88,7% — apoptoza münasibətdə aqonist xüsusiyyətlər, 85,4% — ağciyər xərcəngi zamanı antineoplastik aktivlik. Farmakokinetik analiz göstərir ki, sapolid Lipinskiyin “beş qaydasına” uyğundur, yaxşı bioloji əlçatanlığa malikdir və dərmanabənzərlik meyarlarını ödəyir.

Molekulyar dokinq nəticələrinə görə, sapolid Aurora B kinaza ilə $-10,7$ -dən $-7,4$ kkal/mol, Pregnane X reseptoru ilə isə $-8,8$ -dən $-7,5$ kkal/mol enerji diapazonunda bağlanır. Bu, sapolidin bu hədəflər üçün potensial substrat ola biləcəyini göstərir. Sapolid–Aurora B kinaza kompleksi ehtimal ki, stabil və bioloji cəhətdən aktivdir. Əldə edilən nəticələr sapolidin Aurora B kinaza ilə spesifik və möhkəm bağlanmasını təsdiqləyir ki, bu da onu antitumor aktivliyə malik yeni inhibitorların hazırlanması üçün perspektivli birləşmə edir. Eyni zamanda, Pregnane X reseptoru ilə əmələ gələn kompleks sapolidin bu makromolekul üçün liqand kimi potensial bioloji aktivliyini göstərir.

Açar sözlər: *Saponaria officinalis* L., sapolid, *in silico*, molekulyar dokinq